// App-Quantinova.ai

944 : Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study

Researchers

Presenter

  • Ian Bruce

Principal Investigators

  • Thomas Dorner

  • Manuel Gustavo Leon

  • Piotr Leszczyński

  • Murray Urowitz

  • Birgit Haier

  • Claire Brittain

  • Jiajun Liu

  • Catherine Barbey

  • Christian Stach

Medical Centers

  • Northwell Health, Great Neck, NY

  • University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom

  • Charite Universitaetsmedizin Berlin, Medical Oncology, Berlin, Germany

  • Investigaciones Clínicas, Lima, Peru

  • Poznan University of Medical Sciences, Poznan, Poland

  • University Health Network, University of Toronto, Toronto, ON, Canada

  • UCB Pharma, Monheim, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Biogen, Cambridge, MA

  • Biogen, Baar, Switzerland

Locations

  • United States

  • United Kingdom

  • Germany

  • Peru

  • Poland

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Autoimmune (AI)

Disease

  • Lupus

  • Lupus nephritis

  • Nephritis

Biomarkers

  • N/A

Drug/Treatment

  • Dapirolizumab pegol

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Observational

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved